Comparison of the impact of *Tripterygium wilfordii* Hook F and Methotrexate treatment on radiological progression in active rheumatoid arthritis: 2-year follow up of a randomized, non-blinded, controlled study

Yang-zhong Zhou†, Li-dan Zhao†, Hua Chen†, Yan Zhang‡, Dan-feng Wang, Lin-fang Huang§, Qian-wen Lv∥, Bin Liu||, Zhenbin Li‖, Wei Wei‖‖, Hongbin Li‖‖, Xiangping Liao¶, Hui Liu¶¶, Xiumei Liu¶¶¶, Hongtao Jin¶¶¶¶, Junxiang Wang¶¶¶¶¶, Yun-yun Fei¶¶¶¶¶, Qing-jun Wu¶¶¶¶¶, Wen Zhang¶¶¶¶¶, Qun Shi¶¶¶¶¶, Wen-jie Zheng¶¶¶¶¶, Feng-chun Zhang¶¶¶¶¶, Fu-lin Tang¶¶¶¶¶, Peter E. Lipsky¶¶¶¶¶¶, and Xuan Zhang¶¶¶¶¶¶

**Abstract**

**Background:** *Tripterygium wilfordii* Hook F (TwHF) alone or in combination with methotrexate (MTX) has been shown to be more effective than MTX monotherapy in controlling the manifestations in subjects with disease-modifying antirheumatic drug (DMARD)-naïve active rheumatoid arthritis (RA) over a 6-month period. The long-term impact of these therapies on disease activity and radiographic progression in RA has not been examined.

**Methods:** Patients with DMARD-naïve RA enrolled in the "Comparison of Tripterygium wilfordii Hook F with methotrexate in the Treatment of Active Rheumatoid Arthritis" (TRIFRA) study were randomly allocated into three arms with TwHF or MTX or the two in combination. Clinical indexes and radiographic data at baseline and year 2 was collected and compared using an intent-to-treat (ITT) and a per-protocol (PP) analysis. Two radiologists blinded to the treatment scored the images independently.

(Continued on next page)
Background
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease, characterized by synovitis, systemic inflammation and generation of autoantibodies. In industrialized countries, up to 1.0% of the adult population is affected by RA and suffers from joint damage and loss of physical function [1]. Disease-modifying antirheumatic drugs (DMARDs) are used to treat RA. The most commonly used DMARD is methotrexate (MTX), which is the “anchor drug” for active RA and can be combined with a variety of other drugs. Biological agents can be used when arthritis is aggressive and/or not sufficiently controlled by chemical DMARDs [2]. However, the world wide use of biological agents is restricted by their high costs and risk of severe infections [3].

*Tripterygium wilfordii* Hook F (TwHF) is widely used in traditional Chinese medicine as a potent treatment for joint pain, fever, chills, edema and local inflammation [4, 5]. Extracts of TwHF have been analyzed and the three major diterpenoids, triptolide, triptdiolide and triptonide, are mainly responsible for its anti-inflammatory and immune regulatory activities [6–9]. TwHF has been approved to treat RA in China. Our clinical experiences from treating more than 30,000 patients with RA each year in Peking Union Medical College Hospital (PUMCH) also support the high cost effectiveness of TwHF or a combination of MTX + TwHF, with increases in daily therapeutic expense less than 1 US dollar [10]. Previously in three randomized controlled trials, extracts of TwHF have also been shown to have good efficacy in treating RA compared with placebo or sulfasalazine [11–13].

To further evaluate the role of TwHF in treating RA by comparing its effects to MTX, we recently conducted the “Comparison of *Tripterygium wilfordii* Hook F with methotrexate in the treatment of active rheumatoid arthritis” (TRIFRA) study [14]. In this open-label, multicenter randomized controlled trial, 207 DMARD-naïve patients were randomly allocated into three arms and treated with TwHF, MTX or TwHF+MTX. We evaluated the proportion of patients achieving an American College of Rheumatology (ACR) 50% response (ACR50) at week 24, together with other parameters to measure disease activities including ACR20, ACR70, European League Against Rheumatism (EULAR) good or moderate response, clinical Disease Activity Index (cDAl), 28-joint count Disease Activity Score (DAS28), Health Assessment Questionnaire (HAQ) and 36-item Short-Form Health Survey questionnaire (SF-36) scores. At week 24, ACR50 response was achieved in about half of the patients using MTX or TwHF alone, and in more than three quarters of the patients receiving combination therapy. Similar patterns were found for other parameters. Moreover, with TwHF monotherapy and the combination therapy there was no increased incidence of adverse events compared to MTX alone. Thus, we concluded that TwHF monotherapy was not inferior to, and MTX + TwHF was better than, MTX monotherapy in controlling disease activity safely in patients with active RA [14].

Long-term control of disease activity and associated joint damage, with the preservation of physical function in a safe manner is the ultimate goal of RA management. Therefore, the evaluation of treatment efficacy from long-term trials is needed to determine long-range benefit. Aside from benefit in clinical measures such as ACR50, prevention of joint damage evident on radiography (radiographic joint damage) is an important outcome in determining the long-term treatment effects in clinical trials, and recommended as a surrogate marker for overall functional status in patients with RA [15]. Previous studies have shown that treatment with MTX
or other DMARDs could slow the progression of radiographic damage [16, 17]. The TRIFRA study was designed to be a 24-week, multicenter, randomized controlled trial (RCT). After its termination, the patients continued to be followed, and disease activities were monitored in the real-world situation. Based on changes in perceived disease activity, treatment could be modified accordingly. In this observational report, we followed the participants from the TRIFRA trial for 2 years after the study initiation. Both functional measures and radiological images were collected at year 2 to determine whether the same efficacy patterns observed in the first 24 weeks were sustainable. Moreover, the long-term impact on radiographic progression and physical function was determined.

**Methods**

The TRIFRA study was designed as a 24-week, open-label, randomized study to evaluate the efficacy and safety of TwHF alone, MTX alone or the combination of TwHF + MTX in the treatment of active RA. It was previously registered in ClinicalTrials.gov (NCT01613079). A detailed description of the study design was published previously [14]. After the end of the trial, subjects were followed by the investigators for 18 additional months and monitored using the same clinical outcome measures. In addition, radiographs of the hands and wrists were repeated to evaluate progressive joint damage.

**Patients**

At the time of enrollment, patients eligible for this trial had to meet the following criteria: (1) 18–65 years of age; (2) diagnosed with RA as determined by meeting the 2010 ACR/EULAR classification criteria and having had RA for at least 6 weeks; (3) at least three swollen joints (swollen joint count (SJC)) and five tender joints (tender joint count (TJC)); (4) erythrocyte sedimentation rate (ESR) >28 mm/h or C-reactive protein (CRP) >20 mg/L. Patients who completed 24 weeks in the TRIFRA study continued into the next 18 months of follow up. All patients signed written informed consent at the time of enrollment.

**Study protocol**

The protocol was approved by Peking Union Medical College Hospital (PUMCH) ethical review board. Initially, enrolled participants were allocated into three arms by centralized randomization, as follows: oral TwHF pills 20 mg three times a day; MTX starting from 7.5 mg once a week and increasing to 12.5 mg once a week (0.20–0.25 mg/kg) within 4 weeks, with folic acid 10 mg on the day after each MTX administration; or TwHF plus MTX at the same dosage as aforementioned. In this study, the TwHF used was the same as that in the TRIFRA study, in which the concentration of triptolide (C20H24O5), the major immunosuppressive anti-inflammatory diterpenoid, was 1.2 μg/10 mg, and the concentration of wilforlide (C30H46O3), an anti-inflammatory triterpene, was 36.6 μg/10 mg. The patient’s DAS28 was evaluated at week 12, and monotherapy was continued only if their DAS28 reduced more than 30%; otherwise the patients switched to MTX + TwHF combination therapy. After 24 weeks, patients were followed up and their therapy would be modified based on the physician’s judgement. A detailed description of the study design was published previously and is also shown in Fig. 1.

**Outcomes and measurements**

Similar to the initial 24-week TRIFRA study, though the treating doctors and patients were not blinded to medication allocation, a similar set of clinical efficacy parameters were evaluated in each patient at the end of the second year by trained evaluators who were unaware of the specific therapeutic regimen. The parameters included the ACR criteria [18], HAQ [19], the ESR or serum CRP level, EULAR good or moderate response, cDAI good response (defined as achieving ≥50% improvement in the cDAI, or cDAI ≤2.8) [20], clinical remission (defined as DAS28 <2.6) and low disease activity (LDA) (defined as DAS28 <3.2) [21] and change in HAQ or 36-item Short-Form Health Survey questionnaire (SF-36) scores. The proportion of patients achieving 20% improvement using the ACR criteria was calculated as ACR20, and similarly, the ACR50, and ACR70 were calculated. The safety profile was also recorded.

During the 2 years, radiographic progression was analyzed in patients who had at least two radiographic examinations with time intervals longer than 1 year. Radiographic images of the hands and wrists were independently read by two radiologists who were masked to treatment allocation, time sequence of radiographs and the patient’s clinical response. Joint erosions (JE) and joint space narrowing (JSN) were scored, which were summed to calculate the modified total Sharp score (mTSS) [22]. Inter-reader variability was assessed by the intraclass correlation coefficient and based on status score it ranged from 0.794 to 0.907. To balance the time-interval difference, linear extrapolation of actual change from baseline images was used for patients whose image was missing at the 2-year time point. Mean scores of the two radiographic readers were used for analysis. The radiographic data were reported in a systematic way as recommended [23]. mTSS non-progression was defined as a change from baseline mTSS between −0.5 ~ 0.5 units at 2 years or less than the smallest detectable difference (SDD) [24]. The SDD was computed based on the observed difference between the readers. The estimated yearly mTSS progression at
the baseline was defined as the baseline mTSS score divided by disease duration for each patient.

**Statistical analysis**

Analysis was performed using the modified intent-to-treat (ITT) method, which included all the patients who received the originally allocated treatment at least once. This method was used for the analysis of ACR responses, cDAI responses, EULAR responses, DAS28 remission, ESR, high sensitivity (hs)CRP level, pain measured on a visual analog scale (VAS) and HAQ score at year 2, with missing data interpolated with the last observation carried forward (LOCF) approach. To compare the efficacy variables of MTX monotherapy and TwHF monotherapy, a non-inferiority test was carried out. In the TRIFRA study, the non-inferiority margin was set as 10%, and the required sample size was then calculated accordingly with at least 80% power and 5% level of significance [14]. In this follow-up study, we used the same non-inferiority margin as we did in the TRIFRA study, as the sample size in the ITT analysis was the same. The efficacy variables were compared in the MTX + TwHF group and the MTX monotherapy using the chi square ($\chi^2$) test. We also conducted a per-protocol (PP) analysis that only included the participants who finished the 2-year follow up without violating the originally allocated treatment regimen.

A valid-for-efficacy (VFE) analysis was conducted for radiographic data, including patients who completed the 2-year follow up (completers). Radiographic changes in mTSS, JE and JSN scores were analyzed using analysis of covariance (ANCOVA) with treatment and baseline scores as covariates. Only patients with baseline images and at least one radiographic assessment after the
initiation of treatment were included in the analysis. Radiographic non-progression was defined as an absolute value of the change in mTSS no greater than 0.5, which was analyzed using the $\chi^2$ test.

Categorical data are presented as number (n) or percentage (%). Continuous data are presented as mean (SD) or median (25th–75th centiles). Differences between groups were analyzed for significance using the $\chi^2$ test (categorical data) or ANCOVA with factors for treatment and baseline scores as covariates (continuous data). All analyses were computed using SPSS statistics V.22.0 and SAS V.9.1.

Results
Patients’ follow up and withdrawal information
A total of 207 patients participated in the TRIFRA study. All three treatment groups were well-balanced with respect to baseline demographic and clinical characteristics [14]. Among 207 recruited patients, 33 patients (16%) dropped out in the first 24 weeks mainly because of side effects, inefficacy and protocol violation (Fig. 1). After that, 22 patients (11%) were lost to follow up and 41 patients (20%) refused to return for disease evaluation at year 2. Reasons for refusal included unwillingness because of symptom relief (10/41, 24%), non-medical reasons (22/41, 54%) and unwillingness to disclose information (9/41, 22%). The non-medical reasons mainly include travel expenditure and other personal issues. Two patients died of malignancy. Among 207 recruited patients, a total of 109 patients (53%) returned for the 2-year follow-up evaluation.

As shown in Fig. 1, numbers of patients who withdrew from the study at year 2 were comparable among the MTX monotherapy group (32/69, 46.4%), the TwHF monotherapy group (35/69, 50.7%) and the combination therapy group (31/69, 44.9%) ($p = 0.777$), and the rate of maintaining the initial protocol was not significantly different among the three groups (14/69 (20.3%) in the MTX group, 11/69 (15.9%) in the TwFH group and 22/69 (31.9%) in the combination group, $p = 0.069$). However, there was a trend towards a higher compliance rate among patients in the combination group compared to the other two groups. As aforementioned, the numbers of patients with favorable outcomes (including patients maintaining the initial protocol, patients no longer taking any drugs and patients declining to return for evaluation because of symptom relief) were not significantly different (20/69 (29.0%) in the MTX group, 20/69 (29.0%) in the TwFH group and 29/69 (42.0%) in the combination group, $p = 0.172$), although there was also a trend towards a higher favorable outcome rate among patients in the combination group compared to the other two groups.

Clinical efficacy
Disease activity evaluation
Disease activity was evaluated at year 2 by the ACR criteria, cDAI, EULAR good response, remission rate (DAS28 <2.6) and LDA rate (DAS28 <3.2). In the ITT analysis, we performed a non-inferiority test to compare the TwHF monotherapy group and the MTX monotherapy group, and similar statistical significances were shown in all the parameters: ACR20, 73.9% vs 55.0%; ACR50: 58.0% vs 46.4%; ACR70: 34.8% vs 21.7%; cDAI good response: 72.5% vs 56.5%; EULAR good response, 47.8% vs 23.2%; remission rate, 43.5% vs 17.4%; and LDA rate, 47.8% vs 26.1% ($p < 0.05$) in the TwHF vs MTX group (Table 1). There was a similar pattern at week 24 as described previously [14]. When we compared disease activity in patients from the combination and MTX monotherapy groups, there were significant differences in ACR20, EULAR good response and DAS remission rate at year 2 (ACR 20, 72.5% vs 55.0%; EULAR good response, 40.6% vs 23.2%; remission rate, 34.8% vs 17.4%, respectively ($p < 0.05$) (Table 1).

We also carried out the PP analysis that only included the patients who followed the allocated treatment regimen for 2 years. The results agreed with those found in the ITT analysis. The non-inferiority test was used to compare the TwFH group and MTX group, and showed statistical significances in all the parameters at year 2. However, there was no significant difference between the combination therapy and MTX monotherapy groups (Table 1).

We compared the core components of ACR responses and DAS28 in the three groups (Table 2). All treatment groups had decreases in DAS28 and HAQ scores and increases in SF36 scores, suggesting improvement in functional disability and life quality. However, there was no statistically significant difference in the improvement of these scores among the three groups at year 2 ($p > 0.05$) in either the ITT or the PP analysis (Table 2).

Radiographic outcome
At year 2, paired evaluable radiographic results before and after treatment initiation were available in 109 patients for the VFE analysis (52.7%). Mean TSS at baseline were 28.15, 33.02 and 26.8 in the MTX, TwHF and combination therapy groups, respectively ($p = 0.768$) (Table 3). After 2 years, the mean change from baseline in JE, JSN and TSS were not significantly different among the three treatment groups ($p > 0.05$). The estimated annual radiographic progression was lower in the TwHF and combination group compared with the MTX group. However, there was no statistical significance on ANCOVA with the baseline score as a covariate ($p = 0.615$).

After 2 years, 34.21% of patients receiving combination therapy had no radiographic progression (change from baseline in the mTSS <0.5), compared with 35.29% of patients receiving TwHF and 45.95% of those receiving MTX ($p = 0.520$). In the majority of patients (81.58%) of those receiving combination therapy, 79.41% of those receiving TwHF and 83.78% of those receiving MTX), the change in the TSS was equal to or less than the SDD
the majority of patients in the evaluated independently, changes equal to or less than covariate (mTSS progression when analyzed with treatment as a change in the DAS28 were associated with JE, JSN and the DAS28 during the 2 years. The increasing tertiles of between radiological progression and tertiles of change in JE/JSN progression and disease activity has been reported the three groups were similar, indicating a comparable values close to zero. The plots presenting change within majority of observations in the three treatment groups had were presented in cumulative probability plots to visualize MTX monotherapy was calculated using the gastrointestinal, including nausea, abdominal discomfort and liver dysfunction. Serious infection, such as pneumonia and urinary tract infection, were reported in five patients in the MTX group and two patients in the combination group. Two deaths from malignancy were reported; one subject died of gastric cancer and the diagnosis was unclear in the other subject. Among 170 female patients, 101 were post-menopausal and 17 (10.0%) developed irregular menstruation during the 2-year follow up, including 5 in the MTX group, 7 in the TwHF group and 5 in the combination group (p = 0.744).

In this follow-up study, none of the patients was reported to discontinue the treatment because of adverse events in any of the three arms. Separately, we also compared the side effects reported by the 109 patients who completed the 2-year follow up. Overall, 36.7% of the patients reported adverse events. Among these patients, the most common adverse effects were nausea and liver function abnormalities. Serious infection was not reported in any of the groups.

**Discussion**

The previous 24-week TRIFRA clinical trial is the first RCT that compared the efficacy of TwHF and MTX in treating DMARD-naïve patients with RA [14]. At week 24, TwHF was not inferior to MTX as measured by multiple parameters of disease activity, including ACR20,

| Variables                      | Year 2                  |
|--------------------------------|-------------------------|
|                                | ITT (n = 69)            | TwFH (n = 69) | TwFH vs MTX (n = 69) | TwFH + MTX (n = 69) vs MTX (n = 69) | PP (n = 14) |
| ACR20 response, n (%)          | 38 (55.0%)              | 51 (73.9%)   | p < 0.001            | 50 (72.5%)                         | 8 (57.1%)   | p = 0.034 | 5 (35.7%)       | p < 0.001 | 14 (63.6%) | p = 0.163 |
| ACR50 response, n (%)          | 32 (46.4%)              | 40 (58.0%)   | p = 0.005            | 35 (50.7%)                         | 7 (50.0%)   | 8 (72.7%) | p < 0.001 | 11 (50.0%) | p = 0.312 |
| ACR70 response, n (%)          | 15 (21.7%)              | 24 (34.8%)   | p = 0.001            | 20 (29.0%)                         | 4 (28.6%)   | 4 (36.4%) | p = 0.013 | 7 (31.8%) | p = 0.346 |
| cDAI response, n (%)           | 39 (56.5%)              | 50 (72.5%)   | p = 0.001            | 37 (53.6%)                         | 8 (57.1%)   | 9 (81.8%) | p < 0.001 | 15 (68.2%) | p = 0.110 |
| EULAR good response, n (%)     | 16 (23.2%)              | 33 (47.9%)   | p < 0.001            | 28 (40.6%)                         | 5 (35.7%)   | 7 (63.6%) | p < 0.001 | 9 (40.9%) | p = 0.259 |
| EULAR good to moderate response, n (%) | 50 (72.5%)              | 57 (82.6%)   | p = 0.002            | 59 (85.5%)                         | 12 (85.7%) | 10 (90.9%) | p = 0.003 | 21 (95.5%) | p = 0.072 |
| DAS28 remission, n (%)         | 12 (17.4%)              | 30 (43.5%)   | p < 0.001            | 24 (34.8%)                         | 4 (28.6%)   | 7 (63.6%) | p < 0.001 | 7 (31.8%) | p = 0.346 |
| DAS28 remission and LDA, n (%) | 18 (26.1%)              | 33 (47.9%)   | p < 0.001            | 28 (40.6%)                         | 5 (35.7%)   | 7 (63.6%) | p < 0.001 | 8 (36.4%) | p = 0.784 |

MTX methotrexate, TwHF *Tripterygium wilfordii* Hook F, ACR American College of Rheumatology, cDAI clinical Disease Activity Index, EULAR European League Against Rheumatism, DAS28 28-joint count Disease Activity Score, LDA low disease activity

The number within each bracket represents the patients who reached the response criteria in each group. The percentage of response was calculated with the denominator of total enrolled patients (69 for each group) in the ITT analysis or patients who finished the originally allocated treatment in the PP analysis (14, 11 and 22 for the MTX, the TwHF and the combination groups, respectively). In the ITT analysis, those patients who withdrew from the trial prematurely or switched to the combination group were classed as missing data, which were calculated using the last observation carried forward imputation method when performing the ITT analysis. The p values for comparison between the MTX group and the TwHF group were calculated using the non-inferiority test. Comparison of the combination treatment and MTX monotherapy was calculated using the x2 test.

Side effects

Adverse events were monitored during the 2 years. Overall, 54.6% of the patients reported adverse events, 65% in the MTX, 48% in the TwFH and 51% in the combination group (p = 0.089) (Table 5). Similar to previous reports, the most common adverse effects recorded were gastrointestinal, including nausea, abdominal discomfort and liver dysfunction. Serious infection, such as pneumonia and urinary tract infection, were reported in five patients in the MTX group and two patients in the combination group. Two deaths from malignancy were reported; one subject died of gastric cancer and the diagnosis was unclear in the other subject. Among 170 female patients, 101 were post-menopausal and 17 (10.0%) developed irregular menstruation during the 2-year follow up, including 5 in the MTX group, 7 in the TwHF group and 5 in the combination group (p = 0.744).

In this follow-up study, none of the patients was reported to discontinue the treatment because of adverse events in any of the three arms. Separately, we also compared the side effects reported by the 109 patients who completed the 2-year follow up. Overall, 36.7% of the patients reported adverse events. Among these patients, the most common adverse effects were nausea and liver function abnormalities. Serious infection was not reported in any of the groups.
Table 2 Clinical and laboratory measures in the three groups over 2 years in intention-to-treat (ITT) analysis and per-protocol (PP) analysis

| Variables | Baseline | Year 2 | Year 2 (ITT) | Year 2 (PP) | P |
|-----------|----------|--------|--------------|-------------|---|
|           | MTX (n = 69) | TwFH (n = 69) | TwFH + MTX (n = 69) | MTX (n = 69) | TwFH (n = 69) | TwFH + MTX (n = 69) | MTX (n = 14) | TwFH (n = 11) | TwFH + MTX (n = 22) | P |
| ESR (mm/h) | 54.0 (28.0) | 45.1 (24.6) | 51.6 (25.9) | 27.7 (22.6) | 21.9 (17.9) | 26.7 (27.3) | 20.6 (16.8) | 19.8 (19.0) | 22.7 (26.4) | |
| CRP (mg/L) | 37.5 (40.4) | 27.3 (25.0) | 30.1 (28.7) | 20.6 (13.6) | 11.3 (20.7) | 14.7 (28.6) | 9.0 (18.4) | 9.8 (20.3) | 9.8 (20.3) | 0.760 |
| PGA (mm) | 72.5 (50.0, 90.0) | 70.0 (50.0, 95.0) | 75.0 (50.0, 85.0) | 30.0 (10.0, 50.0) | 31.2 (27.5) | 36.7 (27.4) | 33.2 (31.0) | 29.1 (30.8) | 33.6 (25.5) | |
| TJC | 16.2 (8.3) | 13.8 (7.2) | 15.5 (8.3) | 69.7 (7.1) | 4.5 (8.3) | 6.3 (7.5) | 6.1 (6.3) | 25.3 (4.3) | 0.9 (1.4) | |
| SJC | 91.6 (8.1) | 89.6 (6.7) | 89 (6.7) | 29.4 (4.4) | 2.5 (4.3) | 2.4 (4.6) | 31.0 (4.5) | 0.3 (0.6) | 2.2 (4.2) | |
| HAQ | 1.5 (0.9) | 1.3 (0.9) | 1.4 (0.9) | 12.3 (3.6) | 0.5 (0.7) | 0.6 (0.7) | 26.7 (7.9) | 0.4 (0.6) | 0.6 (0.6) | |
| SF36 | 123.8 (127.0) | 292.6 (155.3) | 279.1 (153.4) | 388.8 (138.4) | 448.9 (152.8) | 417.2 (146.9) | 453.3 (78.3) | 469.7 (70.4) | 445.1 (74.6) | |
| DAS28 | 66.2 (1.31) | 6.22 (1.28) | 6.38 (1.40) | 416 (1.70) | 3.54 (1.69) | 3.95 (1.77) | 382 (1.96) | 2.83 (1.72) | 3.58 (1.63) | |
| Data are presented as mean (standard deviation, SD) and median (interquartile range, IQR) | |
| The p values were calculated using the χ² test |

ESR erythrocyte sedimentation rate, CRP C-reactive protein, PGA Patient's global assessment of disease activity, PhGA Physician's global assessment of disease activity, TJC tender joint count, SJC swollen joint count, HAQ Health Assessment Questionnaire, SF-36 36-item Short-Form Health Survey questionnaire, DAS28 28-joint count Disease Activity Score, MTX methotrexate, TwFH Tripterygium wilfordii Hook F
ACR50 and ACR70 response criteria, EULAR and cDAI good response criteria and DAS28 remission criteria and LDA rate. More importantly, patients with RA receiving MTX + TwHF combination therapy had better improvement in disease activity. Considering that RA is a chronic disease, we followed up the patients from the TRIFRA trial at year 2 and evaluated disease activity in the same way. Among 207 patients recruited in the TRIFRA trial, 109 of them returned for the 2-year follow up. Notably, the frequency of adhering to the initial protocol was comparable among the three groups. The disease activity at year 2 followed a similar pattern when comparing the MTX monotherapy and TwHF monotherapy groups (Table 1). The TwHF was not inferior to MTX in treating active RA. However, the combination therapy was not obviously more effective than MTX monotherapy at year 2. This may suggest that the combination therapy induces disease remission faster in the early stage of treatment, while the long-term efficacy was similar to that in the monotherapy groups. The limited sample size available is a concern at this stage and may have caused bias in the efficacy evaluation.

Aside from the clinical efficacy measures, we also obtained and scored paired radiological images of the hands and wrists from these patients to further objectively validate the efficacy of treatment. Consistent with

| Table 3 Radiographic changes from baseline after 2 years of treatment | MTX (n = 37) | TwHF (n = 34) | MTX + TwHF (n = 38) | P |
|---------------------------------|---------------|---------------|---------------------|---|
| JE at baseline (range 0–280)   |               |               |                     |   |
| mean (SD)                       | 16.76 (22.56) | 20.83 (29.02) | 14.92 (21.26)       |   |
| median (IQR)                   | 7.25 (2.00, 25.00) | 7.00 (2.75, 27.00) | 5.00 (2.75,15.50) | 0.589 |
| JSN at baseline (range 0–168)  |               |               |                     |   |
| mean (SD)                       | 11.92 (15.35) | 13.05 (16.18) | 12.34 (16.06)       |   |
| median (IQR)                   | 6.25 (0, 17.50) | 3.00 (0.75, 30.75) | 5.00 (1.25, 21.00) | 0.957 |
| TSS at baseline                |               |               |                     |   |
| mean (SD)                       | 28.68 (35.54) | 33.88 (42.97) | 26.99 (35.81)       |   |
| median (IQR)                   | 14.75 (2.75, 42.13) | 15.00 (5.00, 47.00) | 14.5 (5.00, 35.25) | 0.738 |
| Estimated annual radiographic progression at baseline† |               |               |                     |   |
| mean (SD)                       | 20.96 (78.12) | 13.02 (15.07) | 10.84 (15.90)       |   |
| median (IQR)                   | 5.74 (1.88, 10.21) | 6.25 (3.51, 20.17) | 5.61 (2.25, 10.37) | 0.635 |
| mTSS at 2 years                |               |               |                     |   |
| mean (SD)                       | 31.94 (37.54) | 36.57 (44.04) | 30.21 (35.99)       |   |
| median (IQR)                   | 15.25 (3.94, 42.00) | 18.00 (5.50, 51.67) | 15.71 (7.41, 38.81) | 0.826 |
| ΔmJE                             |               |               |                     |   |
| mean (SD)                       | 1.59 (4.43)   | 1.33 (2.03)   | 1.44 (3.22)         |   |
| median (IQR)                   | 0 (0, 1.21)   | 0.75 (0, 2.32) | 0.77 (0, 1.50)      | 0.939 |
| ΔmJSN                            |               |               |                     |   |
| mean (SD)                       | 1.67 (3.32)   | 1.31 (2.41)   | 1.78 (3.24)         |   |
| median (IQR)                   | 0 (0, 1.13)   | 0 (0, 1.13)   | 0 (0, 2.19)         | 0.781 |
| ΔmTSS                            |               |               |                     |   |
| mean (SD)                       | 3.24 (6.95)   | 2.70 (3.70)   | 3.22 (5.66)         |   |
| median (IQR)                   | 0.61 (0.418)  | 1.00 (0.414)  | 1.04 (0.362)        | 0.862 |
| ΔmTSS <0.5                      | 17 (45.95%)   | 12 (35.29%)   | 13 (34.21%)         | 0.520 |
| ΔmTSS ≤SDD (5.24)               | 31 (83.78%)   | 27 (79.41%)   | 31 (81.58%)         | 0.893 |
| ΔmJE ≤SDD (3.37)                | 32 (86.49%)   | 31 (91.18%)   | 35 (92.11%)         | 0.691 |
| ΔmTSS ≤SDD (2.85)               | 30 (81.08%)   | 27 (79.41%)   | 31 (81.58%)         | 0.955 |

MTX methotrexate, TwHF Tripterygium wilfordii Hook F, JE joint erosion, JSN joint space narrowing, TSS total Sharp score, mTSS modified total Sharp score, SSD smallest detectable difference

The $p$ values were calculated using analysis of variance for baseline scores, while comparison for estimated progression and scores at year 2 was performed using analysis of covariance with baseline score as a covariate. Comparison of the change in score <0.5 or equal to or less than the smallest detectable difference was conducted using the $\chi^2$ test

†Estimated annual radiological progression at baseline was defined as the baseline mTSS score divided by disease duration for each patient
previous studies [25], radiological progression was associated with disease activity measured by change in the DAS28 (Table 4). This confirmed the functional relevance of the radiological evaluation [26]. Radiographic progression was comparable among the three groups, though the annual radiographic progression trended toward being smaller in the combination group.

Similar to the previous report, the safety profile showed that the frequency of adverse events was not significantly different among the three groups (Table 5). At year 2, the

![Fig. 2 Cumulative probability distribution for the modified total Sharp scores (a), joint erosions (b), and joint space narrowing (c) over the 2 years. MTX, methotrexate; TwFH, Tripterygium wilfordii Hook F](image)

**Table 4** Changes in JE, JSN and mTSS by changes in DAS28 tertiles over 2 years

| ΔDAS28 | JE | JSN | mTSS |
|--------|----|-----|------|
| <2.02, n = 36 | 2.72 (5.08) | 2.66 (4.03) | 5.36 (8.20) |
| 2.02–3.51, n = 36 | 0.85 (2.00) | 0.87 (1.77) | 1.72 (2.86) |
| >3.51, n = 37 | 0.76 (1.40) | 1.23 (2.52) | 2.04 (3.29) |

JE joint erosion, JSN joint space narrowing, mTSS modified total Sharp score, DAS28 28-joint count Disease Activity Score

Data are presented as mean (standard deviation, SD) and median (interquartile range, IQR)

The p values were calculated using analysis of covariance with treatment as covariate

**Table 5** Adverse events in patients

| | MTX (n = 69) | TwFH (n = 69) | TwFH + MTX (n = 69) |
|---|---|---|---|
| All | 45 (65) | 33 (48) | 35 (51) |
| Nausea | 18 (26) | 9 (13) | 17 (25) |
| Diarrhoea | 3 (4) | 2 (3) | 1 (1) |
| Abdominal discomfort | 13 (19) | 9 (13) | 11 (16) |
| Liver dysfunction | 13 (19) | 5 (7) | 8 (12) |
| Serious Infection | 5 (7) | 0 (0) | 2 (3) |
| Baldness | 3 (4) | 2 (3) | 5 (7) |
| Ulcer | 8 (12) | 1 (1) | 6 (9) |
| Irregular menstruation | 5 (7) | 7 (10) | 5 (7) |
| Anemia | 7 (10) | 1 (1) | 6 (9) |
| Leucocytopenia | 4 (6) | 2 (3) | 5 (7) |
| Palpitations | 3 (4) | 0 (0) | 1 (1) |
| Headache | 3 (4) | 1 (1) | 2 (3) |
| Fatigue | 5 (7) | 2 (3) | 1 (1) |
| Weight loss | 3 (4) | 0 (0) | 1 (1) |

MTX methotrexate, TwFH, Tripterygium wilfordii Hook F

Data are presented as number (percentage)
majority of patients who withdrew from the study did not do so in relation to adverse events. The antifertility effect of TwHF was well-known to the participants in our study, and the women recruited were mainly postmenopausal or were not planning to become pregnant. We monitored irregular menstruation in these women, and the incidence was similar among the three groups.

We did not attribute the two cancer deaths to the use of TwHF in this follow-up study. A number of clinical studies on TwHF have not found any association between cancer and TwHF, but rather with RA per se [12, 13, 27]. Notably, the TwHF + MTX combination group in this follow-up study also received the same dosage of TwHF, yet experienced no malignancies. Moreover, numerous pharmacological studies have suggested triptolide has an anti-tumor effect in various tumor models in vitro and in vivo [28, 29].

This study, as a long-term extension of a 24-week RCT, has several limitations. First, this follow-up study, together with the TRIFRA study, was designed as an open-label study. To increase the objectiveness of the results, blinded evaluators were employed. However, a randomized double-blinded trial is needed to provide more robust data and confirm our results. Second, a significant proportion of patients were lost to follow up or changed to other regimens for different reasons. This could bias the analysis, and, therefore, the power of the conclusion was weakened (Fig. 1). Furthermore, there might be significant bias in the analysis of adverse events. In this case, we performed both ITT and PP analysis of all the clinical measures to determine whether similar patterns were observed. Importantly, it was noted that the proportions of patients who withdrew or were lost to follow up were similar among the three groups. It was presumed that patients returned to “real-world” clinical practice and their treatments were monitored and optimized by their physicians’ judgement. Thus, we compared the rate of adherence to the original protocol and performed detailed cause analysis in the follow up, and showed that these were comparable among the three groups. Third, only the radiographic images of the hands and wrists were available for this analysis, and the feet were not included. Studies have shown that the joints of the feet are usually affected earlier than the joints of the hands, and therefore including the feet could help improve the sensitivity of joint damage assessment in early RA [30, 31]. In order to demonstrate the therapeutic efficacy, the patients recruited in the TRIFRA study were diagnosed with definite active RA and the mean disease duration was longer than 60 months. Moreover, considerable radiographic damage was noted in the hands and wrists, providing a reasonable baseline background to determine slowing of radiographic damage, even though the feet were not evaluated. The scores for the hands and wrists were representative of the disease activity at this stage, which was also indicated by its association with change in the DAS28. Ideally, the radiographic data should be obtained uniformly at baseline and the end of year 2. In this real-world follow-up study, we only successfully performed radiographic examination at the end of the 2 years in a proportion of subjects. To further maximize the power of our results, the analysis included all the patients who had at least two radiographic examinations with time intervals greater than 1 year. Notably, we calculated the estimated yearly radiographic progression based on these images. This might introduce additional bias to our results because this model presumed that radiographic progression was linear. Finally, the dose of MTX was limited to 12.5 mg per week and the dose of folic acid was 10 mg per week, which is very common in Asia. This point was discussed in our previous report on the TRIFRA study. As a follow up of the TRIFRA study, the same doses of MTX and folic acid were maintained. Although there has not yet been a direct comparison of the response rates to MTX in patients with RA from different ethnicities, we did notice that the clinical response in our TRIFRA trial was comparable to the data from patients with RA in Europe and North America receiving a higher dose of MTX [32]. We recognized that the response rate in RA may be further improved with more intensive combination treatment [33], although the frequency of adverse events may also increase as well. Most reviews and recommendations suggest a prescription of at least 5 mg folic acid (FA) per week [34]. So far, insufficient evidence has been collected on the optimal dose of FA. Studies have proven that low-dose FA (≤ 7 mg/week) was able to reduce MTX side effects significantly [35]. Doses larger than 5 mg did not lead to further amelioration of the MTX side effects and neither did they affect the efficacy of MTX therapy [36, 37]. Because of these considerations, we are less concerned that the therapeutic effects of MTX were compromised by our use of FA in our study.

This study confirmed the original finding that TwHF was not inferior to MTX in treating active RA in the long term, and that a further study with larger sample sizes should be performed to characterize the role of TwHF in RA therapy in greater detail.

Conclusions
Although this is a follow-up study with several limitations, including the relatively high rates of withdrawal and treatment strategy modifications, data from both the ITT and PP analyses indicate that TwHF monotherapy was not inferior to MTX monotherapy in controlling disease activity and retarding radiographic progression in patients with active RA. This is consistent with the previously published, randomized, controlled, parallel arm, active-comparator TRIFRA study.
Abbreviations
ACR: American College of Rheumatology; cDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28: 28-joint count Disease Activity Score; DMARD: Disease-modifying antirheumatic drug; ESR: Erythrocyte sedimentation rate; FA: Folic acid; HAQ: Health Assessment Questionnaire; ITT: Intent-to-treat; JIE: Joint erosions; ISNJ: Joint space narrowing; LDA: Low disease activity; LOCF: Last observation carried forward; mTSS: Modified total sharp score; MTX: Methotrexate; PP: Per-protocol; PUMCH: Peking Union Medical College Hospital; RA: Rheumatoid arthritis; RCT: Randomized controlled trial; SDD: Smallest detectable difference; SF-36: 36-item Short-Form Health Survey questionnaire; SJC: Swollen joint count; TJC: Tender joint count; TwHF: Tripterygium wilfordii Hook F; VAS: Visual analog scale; VfE: Valid-for-efficacy

Acknowledgements
Not applicable.

Funding
This work was supported by grants from the National Natural Science Foundation of China (81778104, 81630044, 81601432, 81550023, 81325019, 81771763, 81273312, 91542000), Chinese Academy of Medical Science Innovation Fund for Medical Sciences (CIFMS2017-12-M1-008, 2016-12-M1-003, 2017-ZMK-3-011, 2016-12-M1-008), and National Key Research and Development Program: Precise Medical Research (2016YFC0903900).

Availability of data and materials
Please contact the author for data requests.

Authors’ contributions
XZ, HC, WC and W-JZ conceived and designed the study, PEL advised on the study design and the draft of the paper. XZ, WC, QZ, W-JZ, Q-WZ, H-BL, WW, HL, A-JL, H-JJ, J-WX, X-ML, Z-BL, BL, MS, QW, Y-JF, J-MZ, L-DZ, Y-JL, F-IT and F-CZ recruited the patients for this study and recorded information about them. L-FH collected the radiological images for all the patients, and WW, HL, A-JL, H-TJ, J-XW, X-ML, Z-BL, BL, MS, QW, Y-YF, J-MS, L-DZ, YJ, JL, F-IT and F-CZ drafted the paper. XZ and PEL edited and revised the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The original study protocol was approved by the Peking Union Medical College Hospital (PUMCH) ethical review board, and ethical approval for this follow-up study was obtained with the original study, thus further approval was not required. Written informed consent was obtained from each individual.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Clinical Immunology Center, Chinese Academy of Medical Sciences and Peking Union Medical College, The Ministry of Education Key Laboratory, Beijing 100730, China. 2Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 3Formerly National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA. 4Department of Rheumatology, The Affiliated Hospital of QingDao University Medical College, Qingdao, Shandong, China. 5Department of Rheumatology, The Bethune International Healing Hospital of Hebei, Shijiazhuang, Hebei, China. 6Department of Rheumatology, General Hospital of Tianjin Medical University, Tianjin, China. 7Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical College, Hohhot, Inner Mongolia, China. 8Department of Nephrology and Rheumatology, The First People’s Hospital of Chenzhou, Chenzhou, Hunan, China. 9Department of Rheumatology, Beijing Dongfang Hospital, Beijing, China. 10Department of Rheumatology, First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. 11Department of Rheumatology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. 12Department of Rheumatology, Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. 13The Body Sculpture and Liposuction Center of Plastic Surgery Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100144, China. 14AMPJ BioSolutions, Charlottesville, VA 22901, USA.

Received: 3 December 2017 Accepted: 12 March 2018
Published online: 10 April 2018

References
1. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet (London, England). 2010;376:1094–108.
2. O’Dell JR, Mikuls TR, Taylor TH, Akuwunwa V, Brophy M, Warren SR, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369:307–18.
3. Findich A, Bansbach N, Maira CA, Anis AH, Michaud K, Lubin S, et al. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents; a cost-effectiveness analysis. Ann Intern Med. 2009;151:612–21.
4. Wong K-F, Yuan Y, Luk JM. Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents. Clin Exp Pharmacol Physiol. 2012;39:311–20.
5. Tao X, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin N Am. 2000;26:39–50. viii
6. Tao X, Dey M, Yang H, Poulev A, Pouleva R, Donn R, et al. Anti-inflammatory and immunosuppressive compounds from Tripterygium wilfordii. Phytochemistry. 2007;68:1172–8.
7. Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry. 2007;68:732–66.
8. Wang S, Ma L, Tao X, Lipsky PE. Triptolide, an active component of the Chinese herbal remedy Tripterygium wilfordii Hook F, inhibits production of nitric oxide by decreasing inducible nitric oxide synthase gene transcription. Arthritis Rheum. 2004;50:2303–95.
9. Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, et al. Immunosuppressant PG490 (tripotolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem. 1999;274:13443–50.
10. Wang S, Shi Q, Zhao L-D, Li Y, Tang F-L, Zhang F-C, et al. The safety and effectiveness of a chloroform/methanol extract of Tripterygium wilfordii Hook F (T2) plus methotrexate in treating rheumatoid arthritis. J Clin Rheumatol. 2010;16:375–8.
11. Cibere J, Deng Z, Lin Y, Ou R, He Y, Wang Z, et al. A randomized double-blind, placebo controlled trial of topical Tripterygium wilfordii in rheumatoid arthritis: reanalysis using logistic regression analysis. J Rheumatol. 2003;30:465–7.
12. Tao X, Younger J, Fan FZ, Wang B, Lipsky PE. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum. 2002;46:1735–43.
13. Goldberg-Manary RK, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med. 2009;151:229–40. W49–51.
14. Lv Q-W, Zhang W, Shi Q, Zheng W, Li X, Chen H, et al. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. Ann Rheum Dis. 2015;74:1078–86.
15. Landewe R, van der Heijde D. Presentation and analysis of radiographic data in clinical trials and observational studies. Ann Rheum Dis. 2005;64(suppl 4):iv8–51.
16. Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol. 2005;32:590–601.
17. Lipsky PE, van der Heijde DM, St Clair EW, Burfeind FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2003;349:1594–602.
18. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36:729–40.
19. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23:137–45.
20. Aletaha D, Martinez-Avila J, Kvien TK, Smolen JS. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis. 2012;71:1190–6.
21. van der Heijde DM, van ’t Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579–81.
22. van der Heijde DM. Radiographic imaging: the “gold standard” for assessment of disease progression in rheumatoid arthritis. Rheumatology (Oxford). 2000;39(Suppl 1):i9–16.
23. van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum. 2002;47:215–8.
24. Bruyesteyn K, Boers M, Kostense P, van der Linden S, van der Heijde D. Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change. Ann Rheum Dis. 2005;64:179–82.
25. Smolen JS, van der Heijde DM, Keystone EC, van Vollenhoven RF, Goldring MB, Guerette B, et al. Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Ann Rheum Dis. 2013;72:1156–62.
26. van der Heijde D. Erosions versus joint space narrowing in rheumatoid arthritis: what do we know? Ann Rheum Dis. 2011;70(Suppl 1):i16–8.
27. Ge Y, Xie H, Li S, et al. Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial. J Transl Med. 2013;11:134.
28. Phillips PA, Dudeja V, McCarron JA, et al. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 2007;67:9407–16.
29. Yang SM, Chen JG, Guo Z, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther. 2003;2:65–72.
30. Brook A, Cobett M. Radiographic changes in early rheumatoid disease. Ann Rheum Dis. 1977;36:71–3.
31. Hulsmans HM, Jacobs JW, van der Heijde DM, van Albada-Kuipers GA, Schenk V, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum. 2000;43:1927–40.
32. Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156:329–39.
33. Verschueren P, De Cock D, Corluy L, et al. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Ann Rheum Dis. 2015;74:27–34.
34. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis. 2009;68:1086–93.
35. Shea B, Swindon MV, Tanjyong Ghogomu E, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev. 2013;31(S):CD000951. https://doi.org/10.1002/14651858.CD000951.pub2.
36. Morgan SL, Baggett JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial. Ann Intern Med. 1994;121:833–41.
37. Dhir V, Sandhu A, Kaur J, et al. Comparison of two different folic acid doses with methotrexate—a randomized controlled trial (FOLVARI Study). Arthritis Res Ther. 2015;17:156.